|
Nov 6
|
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
|
|
Nov 2
|
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
|
Sep 6
|
3 Healthcare Stocks to Sell in September Before They Crash & Burn
|
|
Aug 11
|
15 Most Important Medical Discoveries in History
|
|
Aug 11
|
Why Shares of Sage Therapeutics Slumped This Week
|
|
Aug 11
|
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
|
|
Aug 11
|
2 Beaten-Down Stocks That Still Aren't Worth Buying
|
|
Aug 8
|
Company News for Aug 8, 2023
|
|
Aug 8
|
Is Sage Therapeutics a Contrarian Buy?
|
|
Aug 8
|
Analysts Just Made A Major Revision To Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Forecasts
|
|
Aug 7
|
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
|
|
Aug 7
|
Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug
|
|
Aug 7
|
Sage Therapeutics Shares Plunge After FDA Rejection
|
|
Aug 7
|
Why Sage Therapeutics Stock Is Crashing Today
|
|
Aug 7
|
Sage shares cut in half after postpartum drug approval. Here's what happened.
|
|
Aug 7
|
FDA approves first postpartum depression pill from Biogen, Sage
|
|
Aug 7
|
Split FDA Call on Depression Drug Upsets Strategies for Biogen, Sage
|
|
Aug 7
|
American Airlines downgraded, United upgraded: Wall Street's top analys
|
|
Aug 7
|
American downgraded, United upgraded: Wall Street's top analyst calls
|
|
Aug 7
|
Sage Tumbles as Depression Pill Approval Omits Major Disorder
|